article thumbnail

Europe’s pharmaceutical packaging market to value over $35bn by 2028

European Pharmaceutical Review

billion in 2028, according to a report by Arizton. billion in 2022, the pharmaceutical packaging and labelling market in Europe is expected to expand at a compound annual growth rate (CAGR) of 4.78 percent up to 2028. This is projected to grow at the highest compound annual growth rate of 5.27 Having been valued at $27.04

Packaging 118
article thumbnail

Global Generic Drug Market Forecast to Hit $531.8 Billion by 2028

Pharmacy Times

Study results show a compound annual growth rate of 5.2% billion in revenue in 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Innovating small molecule injectables: market forecast to 2033

European Pharmaceutical Review

billion in 2028. As such, the compound annual growth rate (CAGR) is expected to be 12.8 A report by the Business Research Company predicts that the small molecule injectable drugs market will value $355.14 percent up to this period.

article thumbnail

Lonza to enhance commercial antibody-drug conjugate supply capacity

European Pharmaceutical Review

The ADC market is expected to grow at a compound annual growth rate (CAGR) of 20 percent between 2023 and 2028, the contract development and manufacturing organisation (CDMO) highlighted. Enhancing manufacturing capabilities The bioconjugates market is currently valued at $33 billion according to research by Lonza.

article thumbnail

Handling HPAPIs safely – what does it take?

European Pharmaceutical Review

” Highly potent APIs are pharmacologically and biologically active compounds at low doses. The compounds require special handling due to their cytotoxicity in the NCEs and investigational new drug applications (INDs). Based on the latest report and data, HPAPI market size is expected to reach $32 billion by 2028.

article thumbnail

Ipsen beefs up in oncology, buying US biopharma Epizyme

pharmaphorum

per share if Tazverik hits $250 million in annual sales in four consecutive quarters before the end of 2026, and $0.70 if the drug is cleared for the second-line FL inflation before 1 January, 2028. Ipsen’s CVR offer includes $0.30 The post Ipsen beefs up in oncology, buying US biopharma Epizyme appeared first on.

article thumbnail

CD19 CAR-T agents to boost blood cancer market

European Pharmaceutical Review

Breyanzi will exhibit the largest compound annual growth rate (CAGR) at 30 percent, compared to Yescarta’s CAGR of 9 percent. Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively. billion in 2031.